Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Chimeric Therapeutics is advancing its ADVENT-AML Phase 1B trial, exploring the innovative use of CORE-NK cell therapy combined with standard AML treatments in newly diagnosed patients who can’t undergo conventional chemotherapy or stem cell transplants. Following successful safety assessments in relapsed AML subjects, the trial now seeks to enroll up to 20 participants at The University of Texas MD Anderson Cancer Center. This groundbreaking approach could redefine first-line AML therapy, offering new hope for improved patient outcomes.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.